Johnson & Johnson Announces Another $1B US Manufacturing Plant
Johnson & Johnson announced plans to invest more than $1 billion in another new, US-based manufacturing site, this time in Florida.
The global pharmaceutical manufacturer’s aim in building the new, Jacksonville facility is to strengthen its Vision operations by scaling US-based manufacturing, packaging, and distribution capabilities, according to a company news release.
The investment also includes advanced manufacturing and packaging technologies to expand capacity and meet growing demand for Johnson & Johnson’s Acuvue brand contact lenses, used by more than 40 million patients worldwide, according to the company. The global pharmaceutical company manufactures more than 1.7 billion Acuvue contact lenses annually for US patients.
“This investment reinforces our long-standing conviction that advanced manufacturing in the United States is essential to delivering innovative, high quality healthcare solutions to patients at home and around the world,” Joaquin Duato, chairman and chief executive officer of Johnson & Johnson, said in the news release.
Duato added in the news release that the investment will bolster the resilience of Johnson & Johnson’s US supply chain.
The global pharmaceutical manufacturer stated in the news release that it initially established a presence in Jacksonville in 1981 and has more than 1.5 million square feet of manufacturing, research, distribution, and operations facilities in the city today.
The new facility is part of the pharmaceutical manufacturer’s previously announced $55 billion US investment in manufacturing, research and development, and technology through early 2029. Construction of the new facility is underway. J&J expects it to be fully operational in 2028.
The investment builds on J&J’s $6 billion annual economic impact in Florida, and supports the continued growth of its Jacksonville operations, strengthening opportunities for the 3,500 employees based in the area while reinforcing the regional economy.
In February, the global drug maker announced another investment of more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, PA. Additionally, in North Carolina, Johnson & Johnson is building a $2 billion drug product manufacturing facility.
The considerable investment is part of a larger push by pharmaceutical manufacturers to onshore or reshore their facilities, in part to avoid tariffs. Companies that are investing in building and expanding US-based facilities and research centers as part of three-year agreements include:
The multinational drug maker also announced plans to invest in a new Pennsylvania-based manufacturing facility — to the tune of more than $3.5 billion — in February.
In September, it started construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, and announced a $1.95 billion investment to expand API production in the US in August 2025.
